含有NR2D的NMDAR的性激活在MPTP注射的帕金森氏症小鼠中加剧了多巴胺基神经损失
Ramesh Sharma1,2,3, Chiranjivi Neupane1,2,3, Thuy Linh Pham1,2
1Department of Biomedicine, Chungnam National University, Daejeon 35015, Republic of Korea.
概括
MPTP中毒会在中脑多巴胺基神经元中招募NR2D子单元,导致持续的NMDA电流,加剧神经元损失和帕金森症模型中的步行缺陷.
科学领域:
- 神经科学是一个神经科学.
- 神经药理学神经药理学
- 分子生物学分子生物学
背景情况:
- 含NR2D亚单元的NMDA受体 (NMDARs) 在发育上受到调节,随着大脑成熟而下降.
- 这些受体可以通过特定的病理生理刺激在成人大脑中被招募.
- 中脑中的多巴氨基 (DA) 神经元对于运动控制至关重要,并且在帕金森病中受到影响.
研究的目的:
- 调查NR2D亚单元含有NMDARs在MPTP诱导的帕金森症中的作用.
- 为了确定MPTP中毒是否在中脑DA神经元中招募NR2D子单元.
- 评估在帕金森病中准NR2D子单元的治疗潜力.
主要方法:
- 在成熟的雄性小鼠中MPTP中毒模型.
- 在DA神经元中测量NMDA电流 (INMDA) 的电生理记录.
- 对NR2D子单元的药理和遗传操纵.
- 对DA神经元损失和步行缺陷的评估.
主要成果:
- MPTP中毒在中脑DA神经元 (SNpc和VTA) 中选择性地招募NR2D-NMDAR.
- 这种招募产生了一种耐 (Mg2+) 的强化剂NMDA电流 (I).
- MPTP增加了中脑区域的NR2D表达.
- 针对NR2D的干预取消了增强力INMDA,减轻了DA神经元损失,并改善了步行缺陷.
结论:
- 超突触NR2D招募产生一个Mg2+耐药的增强剂INMDA,加剧MPTP诱导的帕金森症中DA神经元死亡.
- 含NR2D亚单元的NMDAR是MPTP诱导的神经退行和运动症状的关键因素.
- 国家依赖的NR2D招募代表了在帕金森病和其他神经退行性疾病中神经保护的潜在治疗目标.
相关概念视频
01:24Parkinson's Disease: Treatment
295
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
295
01:15Parkinson's Disease: Overview
592
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
592
01:29Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K